BMRN vs. ILMN: BioMarin Pharmaceutical vs. Illumina Stock Comparison

Company Profile

BioMarin Pharmaceutical (BMRN) and Illumina (ILMN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BMRN is classified in Biotechnology while ILMN is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Illumina (ILMN) has an aggressive beta of 1.46, indicating higher sensitivity to broad-market moves, while BioMarin Pharmaceutical (BMRN) is defensive at 0.24 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

BioMarin Pharmaceutical (BMRN) reports a negative ROE of -0.31%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Illumina (ILMN) reports 32.39%, ranking against industry peers normally.

BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile Illumina (ILMN) reports 19.72%, ranking against industry peers normally.

Both BioMarin Pharmaceutical (BMRN) at 26.58% and Illumina (ILMN) at 20.02% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

BioMarin Pharmaceutical (BMRN) at 12.87% is around its peer norm for revenue growth, while Illumina (ILMN) at -0.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: BioMarin Pharmaceutical (BMRN) reports EPS growth of -18.55%, ranked against its industry; Illumina (ILMN) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Illumina (ILMN) at 2.63 keeps current ratio within its industry’s typical mid-range, while BioMarin Pharmaceutical (BMRN) at 2.44 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BMRN.

Both BioMarin Pharmaceutical (BMRN) at 0.67 and Illumina (ILMN) at 0.74 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Neither BioMarin Pharmaceutical (BMRN) nor Illumina (ILMN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither BioMarin Pharmaceutical (BMRN) nor Illumina (ILMN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Illumina (ILMN) trades at 36.68 times trailing earnings, ranked against its peers, while BioMarin Pharmaceutical (BMRN) has no P/E ratio this period.

BioMarin Pharmaceutical (BMRN) at 2.97 sits in the cheaper P/S ratio quartile while Illumina (ILMN) at 7.10 prices around its industry’s middle — BMRN costs less per dollar of sales, though read it alongside growth and margins.

BioMarin Pharmaceutical (BMRN) at 1.73 is valued about in line with its industry on P/B ratio, while Illumina (ILMN) at 10.30 carries an above-peer premium to book — ILMN is pricier on assets.

Valuation Metrics